Patients Affected By Mcrc Harbouring Braf V600e clinical trials

Explore recruiting patients affected by mcrc harbouring braf v600e clinical trials.

Also recruiting in Europe

Patients Affected By Mcrc Harbouring Braf V600e trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRESSING ON ENCORAFENIB + CETUXIMAB

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Patients Affected By Mcrc Harbouring Braf V600e trials by city

Patients Affected By Mcrc Harbouring Braf V600e in Toronto Patients Affected By Mcrc Harbouring Braf V600e in Vancouver Patients Affected By Mcrc Harbouring Braf V600e in Montreal Patients Affected By Mcrc Harbouring Braf V600e in Calgary Patients Affected By Mcrc Harbouring Braf V600e in Edmonton Patients Affected By Mcrc Harbouring Braf V600e in Ottawa Patients Affected By Mcrc Harbouring Braf V600e in Winnipeg Patients Affected By Mcrc Harbouring Braf V600e in Quebec City Patients Affected By Mcrc Harbouring Braf V600e in Hamilton Patients Affected By Mcrc Harbouring Braf V600e in Kitchener Patients Affected By Mcrc Harbouring Braf V600e in London Patients Affected By Mcrc Harbouring Braf V600e in Halifax Patients Affected By Mcrc Harbouring Braf V600e in New York Patients Affected By Mcrc Harbouring Braf V600e in Los Angeles Patients Affected By Mcrc Harbouring Braf V600e in Chicago Patients Affected By Mcrc Harbouring Braf V600e in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease